Abstract library

145 results for "Van der Horst-Schrivers".
#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#666 Ability of Tumor Markers for Predicting Future Metastatic Disease in MEN-1 Patients with a Pancreatic Neuroendocrine Tumor
Introduction: The diagnostic value of tumor markers in the follow-up of MEN-1 patients with a pancreatic neuroendocrine tumor (pNET) is unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: MD Joanne De Laat
Keywords: MEN-1, tumor marker, pNET, SSA
#946 Immunohistochemical Staining of Catecholamine-Synthesizing Enzymes in Head and Neck Paraganglioma Tissue
Introduction: Head and neck paragangliomas (HNPGLs) are non-producing neuroendocrine tumors, alhough 19-28% of patients have an increased dopamine production. The high sensitivity of 18F-DOPA PET also shows that these tumors might be able to synthesize catecholamines.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Anouk Van der Horst-Schrivers
#1765 Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the Dutch MEN1 Study Group
Introduction: The evidence base when to operate MEN1 related non-functioning pancreatic neuroendocrine tumors (NF-pNETs) is meager.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1
#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group
Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander
#1807 Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance
Introduction: Neuroendocrine carcinoma’s (NEC) are diagnosed by a combination of immunohistochemistry (IHC) and morphology according to the 2010 WHO guidelines.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Wouter Zandee
#2095 Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors
Introduction: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the development of a SI-NET associated mesenteric mass over time.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Drs. Anela Blazevic
#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan